BMNDF (Biomind Labs) Other Long Term Assets: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMNDF Biomind Labs Inc BMNDF
31 GF Score
Price $0.25
! 4 Warning Signs
View Full Analysis

What is Biomind Labs Other Long Term Assets?

Biomind Labs BMNDF 31 Other Long Term Assets is $0.00 Mil as of Jun. 2026. GuruFocus rates BMNDF with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Biomind Labs's other long-term assets for the quarter that ended in Jun. 2026 was $0.00 Mil.

Biomind Labs's annual other long-term assets increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Biomind Labs Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Biomind Labs's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomind Labs Other Long Term Assets Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
0.00 0.00 -0.00 0.00 0.00

Biomind Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BMNDF
31GF Score
Biomind Labs Inc BMNDF
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomind Labs Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.00 Mil mean?
Biomind Labs (BMNDF) has a Other Long Term Assets of $0.00 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Biomind Labs and its competitors.
Is Biomind Labs' Other Long Term Assets too high?
Biomind Labs' current Other Long Term Assets is $0.00 Mil. Overall, Biomind Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomind Labs' Other Long Term Assets compare to VRTX and REGN?
Biomind Labs' Other Long Term Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Biomind Labs and its competitors. Biomind Labs's current Other Long Term Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomind Labs stock overvalued right now?
Biomind Labs (BMNDF) has a current Other Long Term Assets of $0.00 Mil. The current Other Long Term Assets is $0.00 Mil. Biomind Labs' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Biomind Labs (BMNDF), the current Other Long Term Assets is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomind Labs Business Description

Other Exchanges BMND:Canada
Address 701 West Georgia Street, Suite 515, Vancouver, BC, CAN, V7Y 1C6
Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.
31GF Score

Get the complete analysis for BMNDF

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price